Evidence Snapshot

Human immunodeficiency virus

CHEMBL613758 ORGANISM Human immunodeficiency virus

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:02:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:02 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL613758

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Human immunodeficiency virus as ChEMBL target CHEMBL613758. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Human immunodeficiency virus

ORGANISM · Human immunodeficiency virus

As of 2026-09-13

ChEMBL target ID

CHEMBL613758

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Human immunodeficiency virus matters

As of 2026-09-13

Human immunodeficiency virus is reviewed as Human immunodeficiency virus; the current evidence base includes 36 approved drugs, 2004 compounds, and 532 assays, with lead potency reaching pChEMBL 10.0.

Protein context

Human immunodeficiency virus

Review this target as Human immunodeficiency virus.

Protein source · UniProt accession via ChEMBL component mapping

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 36 approved drugs, 2004 compounds, and 532 assays for this target. The dominant activity type is EC50. CHEMBL5314362 is the current potency anchor at pChEMBL 10.0.

Use CHEMBL5314362 as the tractability anchor when discussing potency (pChEMBL 10.0).

Activity source · ChEMBL 36 via Core Engine

36 approved pChEMBL 10.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Human immunodeficiency virus matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2004

Total Compounds

532

Total Assays

Approved Drugs

IC50: 906.0, KI: 6.0, EC50: 1427.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL5314362	10.0	EC50	Approved
No preferred name CHEMBL1078231	9.7	IC50	—
No preferred name CHEMBL5397495	9.5	IC50	—
No preferred name CHEMBL5395699	9.5	IC50	—
No preferred name CHEMBL5412528	9.5	IC50	—

Approved Drugs

Structure	Compound	First Approval
	CABOTEGRAVIR CHEMBL2403238	2021
	DOLUTEGRAVIR CHEMBL1229211	2013
	ELVITEGRAVIR CHEMBL204656	2012
	RILPIVIRINE CHEMBL175691	2011
	ETRAVIRINE CHEMBL308954	2008
	RALTEGRAVIR CHEMBL254316	2007
	RALTEGRAVIR POTASSIUM CHEMBL518520	2007
	DARUNAVIR CHEMBL1323	2006
	TIPRANAVIR CHEMBL222559	2005
	ENTECAVIR CHEMBL5314362	2005
	EMTRICITABINE CHEMBL885	2003
	ATAZANAVIR CHEMBL1163	2003
	LOPINAVIR CHEMBL729	2000
	AMPRENAVIR CHEMBL116	1999
	ABACAVIR CHEMBL1380	1998
	EFAVIRENZ CHEMBL223228	1998
	NELFINAVIR CHEMBL584	1997
	RITONAVIR CHEMBL163	1996
	NEVIRAPINE CHEMBL57	1996
	SAQUINAVIR CHEMBL114	1995
	LAMIVUDINE CHEMBL141	1995
	STAVUDINE CHEMBL991	1994
	ZALCITABINE CHEMBL853	1992
	ZIDOVUDINE CHEMBL129	1987

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:02:48Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 4:02 AM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL613758